Abiopharma

🔍 Gilson Michelle (Executive)

Company: Arcellx, Inc. (ACLX)

Report Date: 2026-04-28

Detailed Transactions and Holdings:

• Sold 67,048 shares of Common Stock (Direct)
  Date: 2026-04-28 | Code: U | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,000 shares of Common Stock (Direct)
  Date: 2026-04-28 | Code: U | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 40,205 shares of Stock Option (right to buy) at $8.66 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2032-05-23 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 32,500 shares of Stock Option (right to buy) at $19.97 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2032-09-28 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 70,796 shares of Stock Option (right to buy) at $31.03 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2033-01-03 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 94,596 shares of Stock Option (right to buy) at $56.15 per share (Derivative)
  Date: 2026-04-28 | Code: D | Expires: 2034-01-02 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 20,496 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-28 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F5, F5, F5
• Sold 61,590 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-28 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F5, F5, F5
• Sold 88,542 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-28 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F5, F5, F5
• Acquired 59,028 shares of Performance-based Restricted Stock Unit (Derivative)
  Date: 2026-04-28 | Code: A | equity_swap_involved: 0 | shares_owned_after: 59,028.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5, F5
• Sold 59,028 shares of Performance-based Restricted Stock Unit (Derivative)
  Date: 2026-04-28 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F5, F5, F5

Footnotes:

• F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
• F2: Shares held by a a family charitable foundation, of which the Reporting Person serves as the President. The Reporting Person has voting and investment power over all securities owned by the foundation.
• F3: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
• F4: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
• F5: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.